| Trial ID: | L0994 |
| Source ID: | ACTRN12617000133336
|
| Associated Drug: |
Nimacimab
|
| Title: |
An Adaptive Design Study for the Assessment of the Safety, Tolerability and Pharmacokinetics of RYI-018 after Single Dosing in Healthy Volunteers and Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
|
| Interventions: |
RYI-018 or placebo.
|
| Outcome Measures: |
--
|
| Sponsor/Collaborators: |
Primary Sponsor Type: Commercial sector/Industry
Primary Sponsor Name: Bird Rock Bio Inc
Primary Sponsor Address: Bird Rock Bio 505 Coast Blvd S, Suite 300 La Jolla, California 92037
Primary Sponsor Country: United States of America
|
| Gender: |
All
|
| Age: |
18 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
--
|
| Study Type: |
--
|
| Study Designs: |
--
|
| Start Date: |
--
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
--
|
| Locations: |
Australia, New Zealand, United States of America
|
| URL: |
https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12617000133336
|
